Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.


Autoria(s): Musat Elena; Roelofs Erik; Bar-Deroma Raquel; Fenton Paul; Gulyban Akos; Collette Laurence; Stupp Roger; Weber Damien C.; Davis J. Bernard; Aird Edwin; Baumert Brigitta G.
Data(s)

2010

Resumo

PURPOSE: Early assessment of radiotherapy (RT) quality in the ongoing EORTC trial comparing primary temozolomide versus RT in low-grade gliomas. MATERIALS AND METHODS: RT plans provided for dummy cases were evaluated and compared against expert plans. We analysed: (1) tumour and organs-at-risk delineation, (2) geometric and dosimetric characteristics, (3) planning parameters, compliance with dose prescription and Dmax for OAR (4) indices: RTOG conformity index (CI), coverage factor (CF), tissue protection factor (PF); conformity number (CN = PF x CF); dose homogeneity in PTV (U). RESULTS: Forty-one RT plans were evaluated. Only two (5%) centres were requested to repeat CTV-PTV delineations. Three (7%) plans had a significant under-dosage and dose homogeneity in one deviated > 10%. Dose distribution was good with mean values of 1.5, 1, 0.68, and 0.68 (ideal values = 1) for CI, CF, PF, and CN, respectively. CI and CN strongly correlated with PF and they correlated with PTV. Planning with more beams seems to increase PTV(Dmin), improving CF. U correlated with PTV(Dmax). CONCLUSION: Preliminary results of the dummy run procedure indicate that most centres conformed to protocol requirements. To quantify plan quality we recommend systematic calculation of U and either CI or CN, both of which measure the amount of irradiated normal brain tissue.

Identificador

http://serval.unil.ch/?id=serval:BIB_4C796391BB4F

isbn:1879-0887[electronic], 0167-8140[linking]

pmid:20378192

doi:10.1016/j.radonc.2010.03.005

isiid:000277936800014

Idioma(s)

en

Fonte

Radiotherapy and Oncology, vol. 95, no. 2, pp. 218-224

Palavras-Chave #Conformal Radiotherapy; Dummy Run; Conformity Indices; Low-Grade Gliomas; Homogeneity; Quality Assurance; Radiation-Therapy; Randomized Trial; European Organization; Cancer-Treatment; Assurance; Oncology; Temozolomide; Prostate
Tipo

info:eu-repo/semantics/article

article